Publications

456 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:
  1. GVS advice midazolam (Midazolam Xiromed®) for the treatment of epilepsy

    The National Health Care Institute has assessed whether oromucosal administration of midazolam (Midazolam Xiromed®) can be ...

    Report | 22-08-2023

  2. GVS advice for tirzepatide (Mounjaro®) for the treatment of adults with type 2 diabetes mellitus without a very high risk of cardiovascular disease

    The National Health Care Institute has assessed whether tirzepatide (Mounjaro®) can be included in the Medicine Reimbursement ...

    Report | 14-08-2023

  3. Advice - Extension of conditional inclusion procedure for ataluren (Translarna®)

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to extend the conditional ...

    Report | 31-07-2023

  4. GVS advice glucagon (Ogluo®) for the treatment of severe hypoglycaemia in adults and children aged 2 years and older

    The National Health Care Institute assessed whether the administration of subcutaneous glucagon (administration under the skin) ...

    Report | 28-07-2023

  5. Package advice for lock procedure medicinal product darolutamide (Nubeqa®) for the treatment of metastatic prostate cancer

    The National Health Care Institute has assessed whether the medicinal product darolutamide in combination with docetaxel and ...

    Report | 28-07-2023

  6. Package advice eptinezumab (Vyepti®) for the treatment of migraine

    The National Health Care Institute has assessed whether the CGRP inhibitor eptinezumab (Vyepti®) can be reimbursed from the basic ...

    Report | 28-07-2023

  7. Package advice for entrectinib and larotrectinib (Rozlytrek® and Vitrakvi®) for the treatment of adult and paediatric patients with solid tumours (cancer) with NTRK gene fusion

    The National Health Care Institute has assessed whether the medicinal products entrectinib and larotrectinib (Rozlytrek® and ...

    Report | 27-07-2023

  8. GVS advice potassium citrate and potassium hydrogen carbonate (Sibnayal®) for the treatment of distal renal tubular acidosis (dRTA)

    The National Health Care Institute has assessed whether the combination preparation potassium citrate and potassium hydrogen ...

    Report | 19-07-2023

  9. Additional GVS advice nirmatrelvir/ritonavir (Paxlovid®) for the treatment of COVID-19

    The National Health Care Institute assessed whether the reimbursement conditions of the subcutaneous CGRP inhibitors erenumab ...

    Report | 13-07-2023

  10. GVS advice on extension of List 2 reimbursement conditions of subcutaneous CGRP inhibitors

    The National Health Care Institute assessed whether the reimbursement conditions of the subcutaneous CGRP inhibitors erenumab ...

    Report | 11-07-2023